By Robb M. Stewart

Eli Lilly & Co. and Boehringer Ingelheim GmbH said Tuesday they achieved the first and only successful trial for heart failure with preserved ejection fraction, with a late stage trial of Jardiance meeting its primary endpoint.

The Emperor-Preserved Phase 3 trial demonstrated significant risk reduction with Jardiance for the composite of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction, a measurement of the percentage of blood the left ventricle pumps out with each contraction, the companies said.

With approval, Jardiance would become the first therapy to improve outcomes for heart-failure patients regardless of ejection fraction, the companies said.

Eli Lilly and Boehringer Ingelheim said the Emperor-Preserved trial compared Jardiance 10 mg with a placebo, and investigated the safety and efficacy of Jardiance in patients with chronic heart failure with preserved ejection fraction. The trial's primary endpoint was time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

07-06-21 0708ET